News & Analysis
News & Analysis

Q3 results give Pfizer a boost

3 November 2021 By Klavs Valters


Pfizer posted their third-quarter financial results before the opening bell on Tuesday. The pharmaceutical giant beat Wall Street estimates.

Pfizer reported total revenue of $24.10 billion in Q3 vs. $21.09 billion expected. Earnings per share at $1.34 a share vs. $1.03 a share estimate.

Dr. Albert Bourla, Chairman and Chief Executive Officer, commented on the latest financial results: ”While we are proud of our third quarter financial performance, we are even more proud of what these financial results represent in terms of the positive impact we are having on human lives around the world. For example, more than 75% of the revenues we have recorded up through third-quarter 2021 for Comirnaty* have come from supplying countries outside the U.S., and we remain on track to achieve our goal of delivering at least two billion doses to low- and middle-income countries by the end of 2022 — at least one billion to be delivered this year and one billion next year, with the possibility to increase those deliveries if more orders are placed by these countries for 2022. One billion of these doses will be supplied to the U.S. government at a not-for-profit price to be donated to the world’s poorest nations at no charge to those countries. Despite all we have been able to accomplish to date, we remain focused on our future, not our past.”

”Our ultimate goal is to help bring this pandemic to an end as quickly as possible, but also to apply the lessons we have learned through our work on the vaccine to all of our therapeutic areas. We look forward to providing future updates on these efforts,” he added.

*Pfizer, BioNTech vaccine

Pfizer Inc. Chart (1Y)

Shares of Pfizer are trading higher following the latest earnings beat, up by around 4% during the trading day on Tuesday. The stock is up by over 26% in the past year at $45.81 per share.

Pfizer is the 37th largest company in the world and 3rd largest pharmaceutical company, with a total market cap of $257.76 billion.

You can trade Pfizer Inc. (PFE) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD. Click here for more information. Trading Derivatives carries a high level of risk.

Sources: Pfizer, Visible Alpha, TradingView

The information provided is of general nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information provided, you should consider whether the information is suitable for you and your personal circumstances and if necessary, seek appropriate professional advice. All opinions, conclusions, forecasts or recommendations are reasonably held at the time of compilation but are subject to change without notice. Past performance is not an indication of future performance. Go Markets Pty Ltd, ABN 85 081 864 039, AFSL 254963 is a CFD issuer, and trading carries significant risks and is not suitable for everyone. You do not own or have any interest in the rights to the underlying assets. You should consider the appropriateness by reviewing our TMD, FSG, PDS and other CFD legal documents to ensure you understand the risks before you invest in CFDs. These documents are available here.

#Economy #Economics #Finance #Markets